Financing accelerates scientific validation and industrial readiness, as round RNAs emerge as a brand new class of brain-derived blood biomarkers with best-in-class efficiency Circular Genomics, Inc., the world-leading developer of round RNA-based precision medication instruments for neurology and psychiatry, at this time introduced the profitable closure of a $15 million Series A financing spherical. The…
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), an organization reworking healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, right this moment introduced a collection of management and governance…
Using a deep studying AI mannequin, researchers recognized the first-of-its-kind biomarker of power stress detectable by means of routine imaging, in line with analysis being introduced subsequent week on the annual assembly of the Radiological Society of North America (RSNA). Chronic stress can have an effect on each bodily and psychological well-being, inflicting a spread of issues…
Adalyon, a pioneering tech-bio firm utilizing its AI-powered speech biomarker platform to remodel scientific drug growth, at present introduced the appointment of Ulrik Zeuthen, as Chief Executive Officer (CEO). Ulrik is an skilled chief in driving digital transformation within the pharmaceutical trade by way of information integration and synthetic intelligence (AI). Adalyon’s proprietary speech-based digital…
Freenome constructing business infrastructure following latest CLIA lab certification and early entry program for key well being system companions, with new take a look at launches for colorectal most cancers, lung most cancers and different indications deliberate in 2026 In beforehand introduced deal, Exact Sciences acquired unique U.S. licensing and commercialization rights to Freenome’s blood-based colorectal…
‘FORTIFY’ Selects FAI-Score as Primary Outcome Measure, and Caristo as Worldwide Imaging Core Lab for Coronary Inflammation and Plaque Measurement and Monitoring Caristo Diagnostics, on a mission to rework the analysis and therapy of heart problems, right this moment, congratulates Abcentra for the profitable dosing of the primary affected person within the FORTIFY medical trial (https://clinicaltrials.gov/examine/NCT06927739), and…
Company expects early 2026 rollout in EEA; doctor portal combines Lumee oxygen monitoring with NVIDIA NeMo to ship AI-driven medical workflows Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a industrial stage digital well being firm pioneering a next-generation expertise platform enabling the continual monitoring of a person’s biochemistry, publicizes the adoption of NVIDIA expertise…
MarketNewsUpdates News Commentary The world Diagnostic Biomarker market is experiencing unprecedented progress and is projected to proceed to see substantial progress in years to return. A current report from the (NIH) National Library of Medicine mentioned the AI-Assisted Biomarker, stated that: “Recently, developments in healthcare digitization and customized therapies have led to groundbreaking developments. Utilization of AI and…
An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) as we speak introduced a unification underneath a single company model, MindWalk, and a change of its Nasdaq ticker image to HYFT. The…
An Evolution in Name, Structure, and Strategy Reflecting the Company’s AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) at this time introduced a unification below a single company model, MindWalk, and a change of its Nasdaq ticker image to HYFT. The…